Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Receivables (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Receivables for 2 consecutive years, with $26.7 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 92.67% to $26.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.7 million through Dec 2025, up 92.67% year-over-year, with the annual reading at $26.7 million for FY2025, 92.67% up from the prior year.
  • Receivables for Q4 2025 was $26.7 million at Day One Biopharmaceuticals, up from $16.7 million in the prior quarter.
  • The five-year high for Receivables was $26.7 million in Q4 2025, with the low at $8.7 million in Q3 2024.